Key regions: Japan, India, Italy, Brazil, South Korea
The Anti-Hypertensive Drugs market in Southern Africa is experiencing steady growth due to various factors.
Customer preferences: Customers in Southern Africa prefer generic drugs due to their affordability. The majority of the population in the region has limited access to healthcare, and therefore, cost is a significant factor when choosing medication. Additionally, patients in the region prefer combination drugs that can treat multiple conditions, such as hypertension and diabetes.
Trends in the market: The demand for Anti-Hypertensive Drugs in Southern Africa is increasing due to the rising prevalence of hypertension in the region. The increasing adoption of sedentary lifestyles and unhealthy diets has contributed to the high incidence of hypertension. As a result, there is a growing need for effective and affordable Anti-Hypertensive Drugs. Moreover, there is a trend towards the use of fixed-dose combination drugs, which can provide better treatment outcomes and improved patient compliance.
Local special circumstances: The Anti-Hypertensive Drugs market in Southern Africa is highly regulated, with strict registration requirements for drugs. The regulatory authorities in the region require that all drugs are registered and approved before they can be sold in the market. Additionally, the region has a high prevalence of counterfeit drugs, which has led to increased regulatory scrutiny of the pharmaceutical industry.
Underlying macroeconomic factors: The economic growth in Southern Africa is driving the demand for Anti-Hypertensive Drugs in the region. The growing middle class in the region has increased access to healthcare, and the demand for quality medication is rising. Additionally, the increasing prevalence of non-communicable diseases, such as hypertension, is driving the demand for Anti-Hypertensive Drugs. The region's pharmaceutical industry is also growing, with increasing investments in research and development, which is driving innovation in the sector.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
